Cargando…

增强免疫组化和原位杂交方法检测非小细胞肺癌的ALK重排的临床可行性

BACKGROUND AND OBJECTIVE: Besides epidermal growth factor receptor (EGFR) mutation, the non-small cell lung cancer (NSCLC) of anaplastic lymphoma kinase (ALK) rearrangement becomes another important clinical subtype. A specific and high-sensitive and economical detection way is convenience for ident...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999847/
https://www.ncbi.nlm.nih.gov/pubmed/25676399
http://dx.doi.org/10.3779/j.issn.1009-3419.2015.02.04
_version_ 1783331530142121984
collection PubMed
description BACKGROUND AND OBJECTIVE: Besides epidermal growth factor receptor (EGFR) mutation, the non-small cell lung cancer (NSCLC) of anaplastic lymphoma kinase (ALK) rearrangement becomes another important clinical subtype. A specific and high-sensitive and economical detection way is convenience for identification of ALK positive NSCLC quickly and accurately. So the objective of our research is to detect ALK rearrangement in 172 cases of NSCLC by using enhancing immunohistochemical way (ventana-IHC, V-IHC). METHODS: ALK rearrangement in 172 NSCLC samples was detected by using V-IHC, and positive staining cases were further verified by fluorescence in situ hybridization (FISH). RESULTS: Among 172 NSCLC cases, there were 12 positive staining. The positive results were confirmed by FISH and 11 cases were FISH positive. The overall concordance between V-IHC and FISH is 91.7% (11/12). CONCLUSION: The V-IHC method is a reliable method for ALK arrangement and could be used in clinical screen and diagnosis.
format Online
Article
Text
id pubmed-5999847
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-59998472018-07-06 增强免疫组化和原位杂交方法检测非小细胞肺癌的ALK重排的临床可行性 Zhongguo Fei Ai Za Zhi Alk阳性nsclc诊治 BACKGROUND AND OBJECTIVE: Besides epidermal growth factor receptor (EGFR) mutation, the non-small cell lung cancer (NSCLC) of anaplastic lymphoma kinase (ALK) rearrangement becomes another important clinical subtype. A specific and high-sensitive and economical detection way is convenience for identification of ALK positive NSCLC quickly and accurately. So the objective of our research is to detect ALK rearrangement in 172 cases of NSCLC by using enhancing immunohistochemical way (ventana-IHC, V-IHC). METHODS: ALK rearrangement in 172 NSCLC samples was detected by using V-IHC, and positive staining cases were further verified by fluorescence in situ hybridization (FISH). RESULTS: Among 172 NSCLC cases, there were 12 positive staining. The positive results were confirmed by FISH and 11 cases were FISH positive. The overall concordance between V-IHC and FISH is 91.7% (11/12). CONCLUSION: The V-IHC method is a reliable method for ALK arrangement and could be used in clinical screen and diagnosis. 中国肺癌杂志编辑部 2015-02-20 /pmc/articles/PMC5999847/ /pubmed/25676399 http://dx.doi.org/10.3779/j.issn.1009-3419.2015.02.04 Text en 版权所有©《中国肺癌杂志》编辑部2015 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle Alk阳性nsclc诊治
增强免疫组化和原位杂交方法检测非小细胞肺癌的ALK重排的临床可行性
title 增强免疫组化和原位杂交方法检测非小细胞肺癌的ALK重排的临床可行性
title_full 增强免疫组化和原位杂交方法检测非小细胞肺癌的ALK重排的临床可行性
title_fullStr 增强免疫组化和原位杂交方法检测非小细胞肺癌的ALK重排的临床可行性
title_full_unstemmed 增强免疫组化和原位杂交方法检测非小细胞肺癌的ALK重排的临床可行性
title_short 增强免疫组化和原位杂交方法检测非小细胞肺癌的ALK重排的临床可行性
title_sort 增强免疫组化和原位杂交方法检测非小细胞肺癌的alk重排的临床可行性
topic Alk阳性nsclc诊治
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999847/
https://www.ncbi.nlm.nih.gov/pubmed/25676399
http://dx.doi.org/10.3779/j.issn.1009-3419.2015.02.04
work_keys_str_mv AT zēngqiángmiǎnyìzǔhuàhéyuánwèizájiāofāngfǎjiǎncèfēixiǎoxìbāofèiáidealkzhòngpáidelínchuángkěxíngxìng
AT zēngqiángmiǎnyìzǔhuàhéyuánwèizájiāofāngfǎjiǎncèfēixiǎoxìbāofèiáidealkzhòngpáidelínchuángkěxíngxìng
AT zēngqiángmiǎnyìzǔhuàhéyuánwèizájiāofāngfǎjiǎncèfēixiǎoxìbāofèiáidealkzhòngpáidelínchuángkěxíngxìng
AT zēngqiángmiǎnyìzǔhuàhéyuánwèizájiāofāngfǎjiǎncèfēixiǎoxìbāofèiáidealkzhòngpáidelínchuángkěxíngxìng
AT zēngqiángmiǎnyìzǔhuàhéyuánwèizájiāofāngfǎjiǎncèfēixiǎoxìbāofèiáidealkzhòngpáidelínchuángkěxíngxìng